SphK Inhibitor

SphK2-IN-4 is a selective SphK2 inhibitor (IC₅₀=6.2 μM) with extremely low activity against SphK1 (IC₅₀ > 50 μM). SphK2-IN-4 exhibits broad-spectrum antiproliferative activity against colorectal cancer cells and induces apoptosis.

VT-ME6 is a selective SphK2 inhibitor with a K_i of 8 µM. VT-ME6 can be used in the research of inflammatory diseases.

SphK2-IN-5 is a selective SphK2 inhibitor with an IC₅₀ of 0.55 μM. SphK2-IN-5 exhibits anticancer activity against colon cancer and liver cancer.

SphK1-IN-3 is an effective sphingosine kinase-1 (SphK1) inhibitor. SphK1-IN-3 inhibits SphK1 kinase activity with an IC₅₀ value of 2.48 μM. SphK1-IN-3 can be used for the research of many diseases such as cancer, rheumatoid arthritis, diabetes, asthma, and pulmonary fibrosis.

Sphk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sphk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Opaganib (Standard) is the analytical standard of Opaganib. This product is intended for research and analytical applications. Opaganib (ABC294640) is a selective, competitive sphingosine kinase 2 (SK2) inhibitor with Ki of 9.8 μM.

SK1-IN-1 (Standard) is the analytical standard of SK1-IN-1 (HY-101805). This product is intended for research and analytical applications. SK1-IN-1 is a potent sphingosine kinase 1 (SPHK1) inhibitor with an IC₅₀ of 58 nM.

SKI-II hydrochloride is an orally active dual-target inhibitor of SphK1/2 and DES1, with K_i values of 16 µM and 0.3 µM against SphK1 and DES1, respectively. SKI-II hydrochloride activates the PERK-Nrf2 antioxidant pathway by stabilizing Nrf2, and synergizes with Temozolomide (HY-17364) to induce oxidative/endoplasmic reticulum stress and cancer cell death under hypoxic conditions. SKI-II hydrochloride inhibits SphK activity, promotes ceramide accumulation and apoptosis, and synergizes with Cisplatin (HY-17394) to reverse drug resistance via the ras/MAPK pathway in vivo. SKI-II hydrochloride reduces measles virus replication by inhibiting mTORC1 activity. SKI-II hydrochloride binds to VCP to induce M1 polarization, enhances host tolerance to Staphylococcus aureus infection, and exerts radioprotective effects through Nrf2 activation and accelerated DNA repair. SKI-II hydrochloride can be used in research related to glioblastoma, acute myeloid leukemia, gastric cancer, measles virus infection, Staphylococcus aureus infection, and acute radiation syndrome.

SphK2-IN-3 (compound 12q) is a selective active sphingosine kinase-2 inhibitor. SphK2-IN-3 has anti-proliferative activity against various cancer cells, inducing G2 phase arrest and apoptosis in liver cancer cells HepG2.

N,N-Dimethylsphingosine-¹³C₂ is the ¹³C-labeled N,N-Dimethylsphingosine (HY-108491). N,N-Dimethylsphingosine is a sphingosine kinase inhibitor. N,N-Dimethylsphingosine binds competitively to sphingosine kinase and blocks the conversion of sphingosine to sphingosine-1-phosphate. N,N-Dimethylsphingosine inhibits sphingosine-1-phosphate release and aggregation of platelets, and also exerts pro-apoptotic effects by resetting ceramide/sphingosine-1-phosphate homeostasis. N,N-Dimethylsphingosine can be used in cancer-related research.

Opaganib (ABC294640) hydrochloride is a selective, competitive sphingosine kinase 2 (SK2) inhibitor with K_i of 9.8 μM.

RB-005 is a selective inhibitor of sphingosine kinase 1 (SK1) (IC₅₀=3.6 µM), with weaker inhibition of another isoenzyme, SK2. The selective inhibition of RB-005 helps to distinguish the biological functions and roles of SK1 and SK2, which can be used in the study of inflammatory diseases and cancer.